Faculty

Adam L. Holtzman, M.D.

Clinical Studies

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC Jacksonville, Fla.
The purpose of this study is to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.

DART 2.0: CtHPV-DNA Informed De-Escalated Adjuvant And Definitive Radiation Therapy (DART 2.0) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary goal of this study is to prospectively incorporate ctHPVDNA in combination with clinical and pathologic factors to appropriately select patients for treatment intensity.